Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm neoadjuvant pembrolizumab + carboplatin + paclitaxel for triple-negative, HER2-negative breast cancer
MOH_2023-08-24_012894Phase 2Not yet recruiting
- Sponsor
- ד"ר יסמין לשם
- Start
- Dec 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, carboplatin and paclitaxel in triple-negative breast cancer (TNBC), sponsored by ד"ר יסמין לשם. Primary endpoint: Pathologic complete response rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2023-08-24_012894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-24_012894.